My post from last week was extracted from the company update on 9/12/14
"With respect to ATL1102 for MS, the Company recently received a positive response from the US Food and Drug Administration following the agency’s Pre-IND assessment of the development strategy for ATL1102, including plans for a Phase IIb trial in MS patients (ASX: ATL1102 for MS – FDA Response to Phase IIb Study Plans, 24 October 2014). Destum have similarly been engaged to help ANP find a suitable development partner for ATL1102. Both ANP and Destum are in ongoing dialogue with potential pharmaceutical company partners. The process of attracting a suitable partner for ATL1102 is anticipated to take up to six months"
The six months is up on the 9 of June.... other projected timelines have been on track so yes i am expecting something soon. Mark had said to others that two weeks either way is not significant so anytime in June or before. This is the one we have been waiting for!!!
- Forums
- ASX - By Stock
- PER
- Ann: ATL1102 Early Access Program for Patients with MS
Ann: ATL1102 Early Access Program for Patients with MS, page-20
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 9.8¢ | $49.85K | 497.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 101000 | 9.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 282099 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 101000 | 0.098 |
1 | 30927 | 0.097 |
2 | 20342 | 0.096 |
1 | 100000 | 0.095 |
3 | 40000 | 0.093 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 282099 | 4 |
0.110 | 353014 | 3 |
0.115 | 583850 | 5 |
0.120 | 381142 | 9 |
0.125 | 110429 | 2 |
Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |